Syngene International announced that during the quarter ended 31 March 2018, the company signed a multiyear strategic collaboration with GSK that will focus on accelerating drug discovery using Syngene's discovery services platform. Syngene will set up customised research facility for GSK with a dedicated team of scientists who will work closely with GSK's global R&D team to identify new drug candidates.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
